Ezetimibe 1.4.51 People with primary hypercholesterolaemia should be considered for ezetimibe treatment in line with NICE's technology appraisal guidance on ezetimibe for treating primary heterozygous-familial and non-familial Other treatment options For other treatment options, see the NICE technology appraisal guidance on our topic page on lipid disorders. Terms used in this guideline High-intensity statin The following doses for statins are high intensity, based on the percentage reduction in low-density lipoprotein (LDL) cholesterol they can produce: atorvastatin: 20 mg to 80 mg rosuvastatin: 10 mg to 40 mg simvastatin: 80 mg. Implementation: getting started This section highlights some important changes to practice that may result from implementing this guideline identified at publication in July 2014. With input from stakeholders, experts and health professionals, 3 areas have been identified that may have a big impact on practice or could be challenging to implement. However, other changes to practice may be needed to fully implement the guideline. Measuring non-high-density lipoprotein cholesterol when lipid profiling for the primary prevention of cardiovascular disease Potential impact of implementation Non-high-density lipoprotein (non-HDL) cholesterol is seen to be a better cardiovascular disease (CVD) risk indicator than low-density lipoprotein (LDL) cholesterol. It is more accurate, more practical and cost effective. A fasting blood sample is not needed. This is more convenient for patients and may reduce the need for additional blood samples. Those requesting lipid profiles for their patients such as GPs, practice nurses and community pharmacists may need to change their practice. Laboratories may also need to change their reporting procedures. Challenges for implementation The United Kingdom National External Quality Assessment Service (UKNEQAS) estimated that less than 10% of laboratories included non-HDL cholesterol in their reports; however, this was primarily due to lack of demand. 